- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02664155
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants (VERDICT)
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic and bleeding complications compared to patients with normal renal function. Direct oral anticoagulants (DOAs) have been shown to be at least as effective and safe as SOC in VTE treatment. But in the clinical trials, moderate renally impaired patients were poorly represented and patients with severe renal insufficiency not at all. So no dose reduction was considered.
Surprisingly, DOAs have been approved for VTE treatment in moderate and severe renally impaired patients. There is need to evaluate a reduced dose of DOAs for VTE treatment in patients with moderate and severe renal insufficiency.
We plan to evaluate reduced doses of 2 DOAs (apixaban, rivaroxaban) compared to SOC in VTE patients with moderate or severe renal insufficiency in terms of net clinical benefit (recurrent VTE and major bleeding) at 3 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic and bleeding complications compared to patients with normal renal function. These patients represent more than 20% of the VTE population in clinical practice. Direct oral anticoagulants (DOAs) have been shown to be at least as effective and safe as SOC in VTE treatment. But in the clinical trials, moderate renally impaired patients were poorly represented (<10%) and patients with severe renal insufficiency not at all. So no dose reduction was considered.
The new DOAs have also been developed for stroke prevention in atrial fibrillation (SPAF). Patients including in AF trials are generally older and more prone to present renal impairment (>20%) than in VTE trials. So a reduced dose of DOAs was evaluated and shown to be at least as effective as, and safer than VKA in the subgroup of patients with moderate renal insufficiency (creatinine clearance between 30 to 50 ml/min).
Surprisingly, DOAs have been approved for VTE treatment and SPAF in moderate and severe renally impaired patients (creatinine clearance between 15 to 30 mL/min). Moreover, patients have to receive a reduced dose of DOAs for SPAF but a full dose of DOAs for VTE that could be associated with an increased bleeding risk, as suggested by some subgroup analyses. So, there, there is need to evaluate a reduced dose of DOAs for VTE treatment in patients with moderate and severe renal insufficiency (creatinine clearance between 15 to 50 mL/min).
Apixaban and rivaroxaban appear to be the best candidates since:
- both are approved in France in VTE patients
- they have mixed pathway of elimination (hepatic and renal)
- they have several other pharmacological similarities and they respective clinical trials have shown similar efficacy and safety profiles when compared with SOC for VTE treatment.
- they do not need to be preceded by initial parenteral heparins on the contrary to dabigatran and edoxaban. This allows evaluating the impact of DOAs in renally impaired patients independently from the initial heparins effect
- a reduced dose regimen is available and approved in AF
- the evaluation of 2 DAOs allows evaluating the concept of this new class in renally impaired VTE patients independently from the pharmaceutical companies.
Finally we plan to evaluate reduced doses of 2 DOAs (apixaban, rivaroxaban) compared to SOC in VTE patients with moderate or severe renal insufficiency in terms of net clinical benefit (recurrent VTE and major bleeding) at 3 months.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Agen, France
- CH d'Agen-Nérac
-
Amiens 1, France, 80054
- CHU Amiens
-
Angers 9, France, 49933
- CHU Angers
-
Besancon, France, 25030
- CH Besancon
-
Bordeaux, France
- CHU de Bordeaux
-
Brest, France, 29200
- CHU La Cavale Blanche Brest
-
Brest, France
- HIA de Brest
-
Castelnau Le Lez, France, 34170
- CHU Castelnau-le-Lez
-
Chartres, France
- CH Louis Pasteur - Chartres
-
Clermont-Ferrand, France, 63003
- CHU Clermont-Ferrand
-
Dijon, France, 21034
- CHU Dijon
-
Grenoble 9, France, 38043
- Hôpital La Tronche Grenoble
-
Ivry sur Seine, France, 94200
- Hôpital Charles Foix - APHP Ivry sur Seine
-
Limoges, France, 87000
- Chu Limoges
-
Lyon, France, 69000
- CHU Lyon
-
Lyon, France
- HCL - Hôpital Edouard Herriot
-
Montpellier 5, France, 34295
- CHU Montpellier
-
Nantes, France
- CHU de Nantes - Hopital Hotel Dieu
-
Nantes, France
- CHU de Nantes - Hôpital Bellier
-
Nice, France, 06003
- CHU Nice
-
Paris, France, 75000
- HEGP - APHP Paris
-
Paris, France, 75000
- Hôpital Louis Mourier- APHP Paris
-
Rouen, France
- CHU de Rouen
-
Saint Etienne, France, 42055
- CHU Saint Etienne
-
Strasbourg, France, 67091
- CHU Strasbourg
-
Toulon, France, 83056
- CH Toulon
-
Toulon, France
- HIA de Toulon
-
Toulouse 9, France, 31059
- CHU Toulouse
-
Valenciennes, France
- CH de Valenciennes
-
-
Boulevard Georges Besnier
-
Arras, Boulevard Georges Besnier, France, 62022
- CH Arras
-
-
Hôpital Trousseau
-
Tours, Hôpital Trousseau, France, 37550
- Chu Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a moderate renal insufficiency defined by a creatinine clearance between 30 to 50 ml/min (Cockcroft and Gault formulae) or a severe renal insufficiency (between 15 to 29 ml/min)
- Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis), planned to be treated for at least 3 months
- Patients >18 years
- Life expectancy more than 3 months
- Social security affiliation
- Signed informed consent
Exclusion Criteria:
- Indication for anticoagulants other than VTE
- Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg
- Anticoagulation for more than 72 hours prior to randomization
- Chronic liver disease or chronic hepatitis
- Patient at high risk of bleeding
- Creatinine clearance <15 ml/min or end stage renal disease or indication for extra-renal dialysis
- Need for concomitant anti-platelet therapy other than aspirin 75-325 mg per day. However concomitant treatment with aspirin is discouraged in this population at bleeding risk.
- Concomitant use of a strong inhibitor of cytochrome P-450 3A4 (CYP3A4) (e.g., a protease inhibitor for human immunodeficiency virus infection or azole-antimycotics agents ketoconazole, itraconazole, voriconazole, posaconazole) or a CYP3A4 inducer (e.g., rifampin, carbamazepine, or phenytoin),
- Active pregnancy or expected pregnancy or no effective contraception
- Any contraindication listed in the local labeling of UFH, LMWH or VKA or oral anticoagulant.
- Cancer-associated VTE requiring long-term treatment with LMWH
- Life expectancy of less than 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DOA : Direct Oral Anticoagulants
The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:
|
Direct Oral Anticoagulant
Other Names:
Direct Oral Anticoagulant
Other Names:
|
ACTIVE_COMPARATOR: SOC : Standard Of Care
The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen.
Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days.
VKA will begin concomitantly and continue for 3 months.
|
Standard Of Care
Standard Of Care
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non inferiority of reduced doses of DOAs
Time Frame: Month 3
|
To demonstrate that reduced doses of DOAs (rivaroxaban or apixaban) are non-inferior to standard of care (heparins/VKA) on the net clinical benefit (recurrent VTE and major bleeding) in renally impaired patients suffering from an acute VTE.
|
Month 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bleeding events
Time Frame: Month 3
|
To demonstrate the non--inferiority of reduced dose of DOAs on the risk of major bleedings.
|
Month 3
|
Venous Thromboembolism (VTE) events
Time Frame: Month 3
|
To demonstrate the non--inferiority of reduced dose of DOAs on the risk of recurrent VTE.
|
Month 3
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: MISMETTI Patrick, MD, CHU Saint Etienne
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Kidney Diseases
- Urologic Diseases
- Embolism and Thrombosis
- Renal Insufficiency
- Thromboembolism
- Venous Thromboembolism
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Protease Inhibitors
- Micronutrients
- Vitamins
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Antifibrinolytic Agents
- Hemostatics
- Coagulants
- Vitamin K
- Rivaroxaban
- Heparin
- Apixaban
Other Study ID Numbers
- 1508189
- 2016-000858-35 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Insufficiency
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
CHU de ReimsUnknownChronic Renal InsufficiencyFrance
-
Vanessa Stadlbauer-Koellner, MDAustrian Science Fund (FWF)CompletedAcute Renal Failure | Chronic Renal InsufficiencyAustria
-
Azienda Sanitaria ASL Avellino 2UnknownChronic Renal InsufficiencyItaly
-
Assistance Publique Hopitaux De MarseilleCompletedChronic Renal InsufficiencyFrance
-
Novartis PharmaceuticalsCompletedChronic Renal InsufficiencyUnited States
-
Weill Medical College of Cornell UniversityGenentech, Inc.SuspendedChronic Renal InsufficiencyUnited States
-
University of Colorado, DenverNational Jewish HealthActive, not recruitingHeart Transplantation | Chronic Renal InsufficiencyUnited States
Clinical Trials on Apixaban
-
PfizerBristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompleted
-
Assistance Publique - Hôpitaux de ParisBristol-Myers SquibbActive, not recruitingCancer-associated ThrombosisFrance, Spain, Netherlands, Belgium, Austria, Greece, Switzerland, Canada, Italy, Poland, United Kingdom
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Portola PharmaceuticalsCompleted
-
Baim Institute for Clinical ResearchBristol-Myers SquibbCompletedAtrial FibrillationUnited States
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
University Hospital, GenevaSunnybrook Health Sciences CentreNot yet recruitingDeep Vein Thrombosis
-
Universitaire Ziekenhuizen KU LeuvenRecruitingAnticoagulation | Short Bowel SyndromeBelgium
-
Artivion Inc.Duke Clinical Research InstituteTerminatedAortic Valve Stenosis | Aortic Valve Disease | Aortic Valve FailureUnited States